Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
7
×
boulder/denver blog main
boulder/denver top stories
clinical trials
7
×
detroit blog main
7
×
detroit top stories
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
novartis
7
×
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech
fda
gene therapy
amgen
glaxosmithkline
immunotherapy
zolgensma
abbvie
abeona therapeutics
biogen
bristol-myers squibb
cancer immunotherapy
What
roundup
7
×
bio
news
biotech
days
democrats
drug
nash
new
abbvie’s
according
advantages
ahead
akcea
alzheimer’s
america
approval
august
bar
biofourmis
biogen
biogen’s
biopharmaceutical
brings
bucks
busy
cancer
cases
celebrate
centers
chance
cigarettes
companies
congress
continues
control
convo
convoluted
corner
day
Language
unset
Current search:
roundup
×
novartis
×
" detroit blog main "
×
" boston top stories "
×
" clinical trials "
×
@xconomy.com
3 years ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com
4 years ago
Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
5 years ago
Bio Roundup: Head and Spine Previews, Biogen Moves, IPO Dreams & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: Midterm Fallout, Alzheimer’s Search, Postpartum Panel